<scp>RondH</scp> Peptide: Antitumor Effects in Murine Melanoma Cells

ABSTRACT The study is investigating the efficacy of the peptide RondH in inhibiting the development of murine melanoma. Peptides are promising due to their ability to interact with specific targets in cancer cells while exhibiting low toxicity. Rondonin, an antifungal peptide, different from its derivative RondH, has shown antitumoral activity. In vitro experiments demonstrated the non‐cytotoxicity of RondH in cells such as VERO, HeLa, and Y1; however, it showed a cytotoxic effect in murine melanoma B16F10‐Nex2 cells. In vivo models, RondH‐treated mice showed a significant reduction in the development of metastatic lung nodules compared to the control group. In addition, histopathological analysis showed no toxicity in organs such as the spleen, heart, liver, lung, and kidney. These results suggest the therapeutic potential of RondH in the treatment of metastatic melanoma and highlight the importance of peptides as antitumoral agents with potential future clinical applications.